The promoter group of Aarti Drugs Limited has reduced its stake in the company by 1.67% through a series of market sales and buyback transactions between May 29, 2024, and June 24, 2026. The disclosure, submitted pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details the changes in shareholding by Dilesh Roadlines Private Limited and other members of the promoter group. The total equity share capital of the company decreased from 91,935,000 to 91,270,000 shares following a buyback of 665,000 shares in September 2024.

Shareholding Changes

The transactions resulted in a net disposal of 2,265,795 shares by the promoter group. Dilesh Roadlines Private Limited sold 125,998 shares, while other promoters disposed of 1,769,641 shares. Conversely, the group purchased 370,156 shares through market mechanisms during the specified period. The total promoter and promoter group holding, which previously stood at 55.70%, has now adjusted to 54.43% of the total paid-up capital.

Breakdown of Transactions

The following table summarizes the shareholding changes for the promoter group:

Regulatory Context

The filing was made to the National Stock Exchange of India Limited and BSE Limited to comply with disclosure requirements regarding substantial acquisition and disposal of shares. The reduction in stake is attributed to market sales and the company's buyback program. The diluted share capital used for percentage calculations remained consistent with the equity share capital post-buyback, as there were no outstanding convertible securities or warrants.

Aarti Drugs will host a group meeting for analysts and institutional investors on June 23, 2026, at Tarapur, Maharashtra. The meeting is scheduled to take place between 10:00 AM and 3:30 PM. The company stated that discussions during the interaction will be based solely on publicly available information.

The disclosure was made pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Aarti Drugs clarified that no unpublished price sensitive information (UPSI) is intended to be shared during the proceedings.

The schedule for the meeting is detailed below:

Rushikesh Deole, Company Secretary & Compliance Officer, signed the intimation sent to the stock exchanges. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.